- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03069534
Study of Adjunctive Recombinant Human Interleukin-2 Therapy in Patients With MDR-TB (rhIL-2)
Study of Adjunctive rhIL-2 Therapy in Patients With MDR-TB That Improves Efficiency and Shortens Course
Study Overview
Detailed Description
IL-2 therapy regimans are expected to restore the immune response or to change the immunologic status,thus allowing the host to more efficiently contain and eradicate immune responses, primarily those against cancers and infectious diseases.To address this, we performed a prospective randomized controlled multicenter cohort study of 8-month adjunctive immunotherapy with rhIL-2 for MDR-TB patients compared with the standard chemotherapy.
This multicenter prospective clinical study was conducted at 13 tuberculosis centers (coordinating hospital specialized in tuberculosis) across Jiangsu province, China. Joined by the network system of The First Affiliated Hospital of Nanjing Medical University and CDC of Jiangsu province, participants were enrolled from 2009 to 2018. This study protocol was approved by the ethics committee of the First Affiliated Hospital of Nanjing Medical University and was performed adhering to the ethical principles of the Declaration of Helsinki. All patients provided written informed consent before enrollment. The independent data and safety of the study were monitored by the hospital monitoring committee.
Patients enrollment
Eligible MDR-TB participants were identified by triplicate-spot sputum smears that were positive for acid-fast bacilli and a positive sputum culture with resistance to both isoniazid and rifampin, as determined by susceptibility tests and rapid screening tests . The results of these assays were confirmed using an L-G medium base modified in the Jiangsu province Centers for Disease Control and Prevention(CDC).
Treatment plan for the two cohorts: The patients in rhIL-2 group were given consisted of four courses of low-dose rhIL-2 (500,000 U/m) given subcutaneously (SC) once every other day (q.o.d.) for 30 days. Four courses were carried out separately during months 1, 3, 5, and 7. All enrolled patients with pulmonary MDR-TB received a 24-month standard anti-MDR-TB chemotherapy regimen:6-month Z+KM/AM or CM + PAS/(Pa) + PTO +LFX as an intensive phase treatment, followed by an 18-month Z + LFX + PTO + PAS/(Pa) as a consolidation phase treatment.
(Z: Pyrazinamide; KM: Kanamycin; AM: Amikacin; CM: Capreomycin; LFX: Levofloxacin; PTO: Prothionamide; PAS: Para-aminosalicylicacid; Pa:Pasiniazid); After finishing treatment regimen patients were followed up for a minimum of 36- months or until discontinuation of regimen, withdrawal of consent, loss to follow-up, death, or end of study.
For all of the participants demographic measurements were recorded on the first clinical visit. Patient data were collected at enrollment and quarterly intervals. Sputum smear conversion, sputum culture conversion and chest CT scan improvement were followed up at 3, 6, 12, 18, and 24 months for bacteriological and imaging data collected. Cure rates analysed and compared in both groups.
The proportions of MDR-TB patients in the two groups achieving sputum smear/culture conversion, lung lesions absorption were assessed and compared.
Safety assessment included clinical symptom observation, Incidences of adverse event (AE )in two groups were assessed and compared. blood routine test, hematologic profile, blood biochemical examination including hepatic aminotransferase and blood ureantrogen/creatinine, blood electrolyte test (potassium, magnesium, calcium), serum thyroid stimulating hormone(TSH), audiology examinations, visual field and color examination.
Cure rate was defined as first outcome. Sputum conversion rate was defined as second outcome.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
- Name: Qi Tan, PH.D
- Phone Number: +8613584097282
- Email: aqua18345760@hotmail.com
Study Locations
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210029
- Recruiting
- The First Affiliated Hospital of Nanjing Medical University
-
Contact:
- Qi Tan, PH.D
- Phone Number: +8613584097282
- Email: aqua18345760@hotmail.com
-
Sub-Investigator:
- Qi Tan, PH.D
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients had/were:
- a confirmed case of MDR-TB;
- aged 18-70 years old;
- a chest CT showing visible lung lesions, with or without holes;
- a fasting plasma glucose of less than 7.8 mol/L and a normal fundus examination, if they were diabetic;
- voluntarily joined this study and signed an informed consent form.
Exclusion Criteria:
- two or more total allergies or any drug or food allergies;
- resistant to some drugs of this program;
- severe disorders of liver, kidney, or hematologic system functions;
- any metabolic diseases, autoimmune diseases, endocrine diseases, cancer, or HIV/AIDS;
- a long-term use of immunosuppressive agents;
- a blood system dysfunction;
- a history of mental illness or epilepsy;
- pregnant or lactating;
- participated in another clinical trial in the last 3 months or were currently participating in other ongoing clinical trials;
- long-term alcohol abuse>10 years and more than two alcoholic drinks per day);
- any other factor rendering them unsuitable to participate in this project, such as a history of unreliability.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: rhIL-2 Group
The patients in rhIL-2 Group were given consisted of four courses of low-dose rhIL-2 plus standard anti-tuberculosis chemotherapy.
rhIL-2 (500,000U/m)regiman was given subcutaneously (SC) once every other day (q.o.d.) for 30 days and four courses were carried out separately during months 1, 3, 5, and 7. Standard anti-MDR-TB chemotherapy regiman was totally 24 months,including 6-month Z+KM/AM or CM + PAS/(Pa) + PTO +LFX as an intensive phase treatment, followed by an 18-month Z + LFX + PTO + PAS/(Pa) as a consolidation phase treatment.Then all the group patients were followed up for a minimum of 36 months.
|
RhIL-2 treatment intervention was consisted of four courses of low-dose rhIL-2 plus standard anti-tuberculosis chemotharapy.
rhIL-2 (500,000 U/m)regimen was given subcutaneously (SC) once every other day (q.o.d.) for 30 days and four courses were carried out separately during months 1, 3, 5, and 7.
|
NO_INTERVENTION: Control Group
The patients in Control Group were given standard anti-tuberculosis chemotherapy regiman.Standard anti-MDR-TB chemotherapy regiman was totally 24 months,including 6-month Z+KM/AM or CM + PAS/(Pa) + PTO +LFX as an intensive phase treatment, followed by an 18-month Z + LFX + PTO + PAS/(Pa) as a consolidation phase treatment.Then all the group patients were followed up for a minimum of 36 months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cure rate
Time Frame: 130 months
|
Completion of treatment and at least five consecutive negative sputum cultures from samples collected at least 30 days apart or one positive sputum culture followed by a minimum of three consecutive negative cultures taken at least 30 days apart during the final 12 months of treatment;
|
130 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
sputum smear/culture conversion rate
Time Frame: 24 months
|
The proportions of MDR-TB patients in the two groups achieving sputum smear/culture conversion at the end of 24 months of treatment
|
24 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Hong Wang, PH.D, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- rhIL-2 Therapy ON MDR-TB
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on MDR TB
-
Centre for the AIDS Programme of Research in South...Amsterdam Institute for Global Health and Development; Global Alliance for... and other collaboratorsRecruitingTuberculosis | Drug Resistant Tuberculosis | MDR-TB | XDR-TBNigeria, South Africa, Ethiopia
-
Shanghai Pulmonary Hospital, Shanghai, ChinaHuashan Hospital; Shanghai Public Health Clinical Center; No.85 Hospital, Changning...RecruitingImmunotherapy | MDR-TBChina
-
Shanghai Pulmonary Hospital, Shanghai, ChinaHuashan Hospital; Shanghai Public Health Clinical Center; Anhui Chest Hospital; No.85 Hospital, Changning, Shanghai, China and other collaboratorsRecruiting
-
IUATLD, IncMedical Research Council; Institute of Tropical Medicine, Belgium; Liverpool... and other collaboratorsCompletedMDR-TBEthiopia, Georgia, India, Moldova, Republic of, Mongolia, South Africa, Uganda
-
Jan-Willem C AlffenaarUniversity of Virginia; Kibong'oto Infectious Diseases HospitalCompleted
-
Global Alliance for TB Drug DevelopmentCompletedTuberculosis | Tuberculosis, Pulmonary | Tuberculosis, Multidrug-Resistant | Extensively Drug-Resistant Tuberculosis | Tuberculosis, MDR | XDR-TB | Pre-XDR-TBSouth Africa, Russian Federation, Georgia, Moldova, Republic of
-
Ina-RespondNational Institute of Health Research and Development, Ministry of Health... and other collaboratorsCompletedLung Tuberculosis | MDR TBIndonesia
-
University of OxfordCompleted
-
University of OxfordCompleted
-
University of OxfordMedical Research CouncilCompleted
Clinical Trials on RhIL-2
-
Assistance Publique - Hôpitaux de ParisIltoo PharmaCompletedType 1 DiabetesBelgium, France, Germany, Netherlands, Sweden, Switzerland
-
Celularity IncorporatedCompleted
-
University of ChicagoCompletedMetastatic MelanomaUnited States
-
Cytheris SACompletedHIV Infections | LymphopeniaUnited States, France, Canada, Italy
-
Cytheris, Inc.CompletedAML | MDS | CMLUnited States
-
Wyeth is now a wholly owned subsidiary of PfizerTerminatedUlcerative Colitis | Inflammatory Bowel Disease
-
NeoImmuneTechNational Institute of Allergy and Infectious Diseases (NIAID); University of...Terminated
-
PT Kalbe Genexine BiologicsGenexine, Inc.Recruiting
-
Genexine, Inc.Terminated
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI); Cancer Immunotherapy Trials NetworkCompletedCastration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer | Castration Levels of TestosteroneUnited States